Review top news and interview highlights from the week ending August 12, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The 2 deaths, due to acute liver failure, occurred in patients treated in Kazakhstan and Russia.
A recent comparison of health-related quality of life scores also favored ide-cel over belantamab mafodotin treatment.
No such adverse events have occurred in the lower-dose group.
Nula-cel is intended to directly correct the mutation that causes sickle cell disease.
PBFT02, developed by Passage Bio, is delivered via intra cisterna magna administration to the brain.
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.